Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease

키워드

참고문헌 (106)

1. Younossi Z, "Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates", Clin Gastroenterol Hepatol, 17, pp.748~755.e3 (2019)
2. Byrne CD, "NAFLD : a multisystem disease", J Hepatol, 62(1 Suppl), pp.S47~S64 (2015)
3. 김경수, "Nonalcoholic Fatty Liver Disease and Diabetes: Part II: Treatment", Diabetes and Metabolism Journal, 43(2), pp.127~143 (2019), 대한당뇨병학회[DOI]
4. 이은정, "Nonalcoholic Fatty Liver Disease and Diabetes: An Epidemiological Perspective", Endocrinology and Metabolism, 34(3), pp.226~233 (2019), 대한내분비학회[DOI]
5. Vernon G, "Systematic review : the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults", Aliment Pharmacol Ther, 34, pp.274~285 (2011)
6. 이상배, "Triglyceride Glucose Index Is Superior to the Homeostasis Model Assessment of Insulin Resistance for Predicting Nonalcoholic Fatty Liver Disease in Korean Adults", Endocrinology and Metabolism, 34(2), pp.179~186 (2019), 대한내분비학회[DOI]
7. Arrese M, "Concurrent nonalcoholic fatty liver disease and type 2 diabetes : diagnostic and therapeutic considerations", Expert Rev Gastroenterol Hepatol, 13, pp.849~866 (2019)
8. Xia MF, "NAFLD and diabetes : two sides of the same coin? Rationale for gene-based personalized NAFLD treatment", Front Pharmacol, 10, pp.877~ (2019)
9. 이용호, "Nonalcoholic Fatty Liver Disease in Diabetes. Part I: Epidemiology and Diagnosis", Diabetes and Metabolism Journal, 43(1), pp.31~45 (2019), 대한당뇨병학회[DOI]
10. Fracanzani AL, "Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels : a role for insulin resistance and diabetes", Hepatology, 48, pp.792~798 (2008)
11. Ulasoglu C, "Characterization of patients with biopsy-proven non-alcoholic fatty liver disease and normal aminotransferase levels", J Gastrointestin Liver Dis, 28, pp.427~431 (2019)
12. Kim SK, "Nonalcoholic fatty liver disease is associated with increased carotid intima-media thickness only in type 2 diabetic subjects with insulin resistance", J Clin Endocrinol Metab, 99, pp.1879~1884 (2014)
13. Kim BY, "Prevalences of diabetic retinopathy and nephropathy are lower in Korean type 2 diabetic patients with non-alcoholic fatty liver disease", J Diabetes Investig, 5, pp.170~175 (2014)
14. Younossi ZM, "The global epidemiology of NAFLD and NASH in patients with type 2 diabetes : a systematic review and meta-analysis", J Hepatol, 71, pp.793~801 (2019)
15. European Association for the Study of the Liver (EASL), "EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease", J Hepatol, 64, pp.1388~1402 (2016)
16. 장지은, "Effectiveness of Exercise Intervention in Reducing Body Weight and Glycosylated Hemoglobin Levels in Patients with Type 2 Diabetes Mellitus in Korea: A Systematic Review and Meta-Analysis", Diabetes and Metabolism Journal, 43(3), pp.302~318 (2019), 대한당뇨병학회[DOI]
17. Sanchez-Rangel E, "Metformin : clinical use in type 2diabetes", Diabetologia, 60, pp.1586~1593 (2017)
18. Rena G, "The mechanisms of action of metformin", Diabetologia, 60, pp.1577~1585 (2017)
19. 김미경, "2019 Clinical Practice Guidelines for Type 2 Diabetes Mellitus in Korea", Diabetes and Metabolism Journal, 43(4), pp.398~406 (2019), 대한당뇨병학회[DOI]
20. 강유미, "Effectiveness and Safety of Adding Basal Insulin Glargine in Patients with Type 2 Diabetes Mellitus Exhibiting Inadequate Response to Metformin and DPP-4 Inhibitors with or without Sulfonylurea", Diabetes and Metabolism Journal, 43(4), pp.432~446 (2019), 대한당뇨병학회[DOI]
21. Lin HZ, "Metformin reverses fatty liver disease in obese, leptin-deficient mice", Nat Med, 6, pp.998~1003 (2000)
22. Song YM, "Metformin alleviates hepatosteatosis by restoring SIRT1-mediated autophagy induction via an AMP-activated protein kinase-independent pathway", Autophagy, 11, pp.46~59 (2015)
23. Marchesini G, "Metformin in non-alcoholic steatohepatitis", Lancet, 358, pp.893~894 (2001)
24. Lavine JE, "Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents : the TONIC randomized controlled trial", JAMA, 305, pp.1659~1668 (2011)
25. Rakoski MO, "Meta-analysis : insulin sensitizers for the treatment of non-alcoholic steatohepatitis", Aliment Pharmacol Ther, 32, pp.1211~1221 (2010)
26. Musso G, "A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease", Hepatology, 52, pp.79~104 (2010)
27. Li Y, "Metformin in non-alcoholic fatty liver disease : a systematic review and meta-analysis", Biomed Rep, 1, pp.57~64 (2013)
28. Chalasani N, "The diagnosis and management of nonalcoholic fatty liver disease : practice guidance from the American Association for the Study of Liver Diseases", Hepatology, 67, pp.328~357 (2018)
29. Cunha V, "Metformin in the prevention of hepatocellular carcinoma in diabetic patients : a systematic review", Ann Hepatol, 19, pp.232~237 (2020)
30. Promrat K, "A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis", Hepatology, 39, pp.188~196 (2004)
31. Belfort R, "A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis", N Engl J Med, 355, pp.2297~2307 (2006)
32. He L, "Thiazolidinediones for nonalcoholic steatohepatitis: a meta-analysis of randomized clinical trials", Medicine(Baltimore), 95, pp.e4947~ (2016)
33. Singh S, "Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis : a systematic review and network meta-analysis", Hepatology, 62, pp.1417~1432 (2015)
34. Sanyal AJ, "Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis", N Engl J Med, 362, pp.1675~1685 (2010)
35. Cusi K, "Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus : a randomized trial", Ann Intern Med, 165, pp.305~315 (2016)
36. Musso G, "Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis : a metaanalysis", JAMA Intern Med, 177, pp.633~640 (2017)
37. Iogna Prat L, "The effect of antidiabetic medications on non-alcoholic fatty liver disease(NAFLD)", Hormones(Athens), 17, pp.219~229 (2018)
38. Kim SG, "Efficacy and safety of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 24-weeks : a multicenter, randomized, double-blind, parallel-group, placebo controlled trial", PLoS One, 9, pp.e92843~ (2014)
39. Choung S, "Treatment with lobeglitazone attenuates hepatic steatosis in diet-induced obese mice", PPAR Res, 2018, pp.4292509~ (2018)
40. Lee YS, "The antidiabetic drug lobeglitazone protects mice from lipogenesisinduced liver injury via mechanistic target of rapamycin complex 1inhibition", Front Endocrinol(Lausanne), 9, pp.539~ (2018)
41. 이용호, "Lobeglitazone, a Novel Thiazolidinedione, Improves Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: Its Efficacy and Predictive Factors Related to Responsiveness", Journal of Korean Medical Science, 32(1), pp.60~69 (2017), 대한의학회
42. Baggio LL, "Biology of incretins : GLP-1 and GIP", Gastroenterology, 132, pp.2131~2157 (2007)
43. 강유미, "Asian Subpopulations May Exhibit Greater Cardiovascular Benefit from Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A Meta-Analysis of Cardiovascular Outcome Trials", Diabetes and Metabolism Journal, 43(4), pp.410~421 (2019), 대한당뇨병학회[DOI]
44. García Díaz E, "Effect of incretin therapies compared to pioglitazone and gliclazide in non-alcoholic fatty liver disease in diabetic patients not controlled on metformin alone : an observational, pilot study", Endocrinol Nutr, 63, pp.194~201 (2016)
45. Sathyanarayana P, "Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes", Obesity(Silver Spring), 19, pp.2310~2315 (2011)
46. Blaslov K, "Effect of exenatide therapy on hepatic fat quantity and hepatic biomarkers in type 2 diabetic patients", Clin Res Hepatol Gastroenterol, 38, pp.e61~e63 (2014)
47. Dutour A, "Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes : a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy", Diabetes Obes Metab, 18, pp.882~891 (2016)
48. Bi Y, "Effects of exenatide, insulin, and pioglitazone on liver fat content and body fat distributions in drug-naive subjects with type 2 diabetes", Acta Diabetol, 51, pp.865~873 (2014)
49. Armstrong MJ, "Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes : individual patient data meta-analysis of the LEAD program", Aliment Pharmacol Ther, 37, pp.234~242 (2013)
50. Tian F, "Efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease", Biosci Rep, 38, pp.BSR20181304~ (2018)
51. Petit JM, "Effect of liraglutide therapy on liver fat content in patients with inadequately controlled type 2 diabetes : the Lira-NAFLD Study", J Clin Endocrinol Metab, 102, pp.407~415 (2017)
52. Khoo J, "Randomized trial comparing effects of weight loss by liraglutide with lifestyle modification in non-alcoholic fatty liver disease", Liver Int, 39, pp.941~949 (2019)
53. Armstrong MJ, "Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis(LEAN) : a multicentre, double-blind, randomised, placebo-controlled phase 2 study", Lancet, 387, pp.679~690 (2016)
54. Eguchi Y, "Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients(LEAN-J)", Hepatol Res, 45, pp.269~278 (2015)
55. Gluud LL, "Effects of lixisenatide on elevated liver transaminases : systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetes", BMJ Open, 4, pp.e005325~ (2014)
56. Cusi K, "Dulaglutide decreases plasma aminotransferases in people with type 2 diabetes in a pattern consistent with liver fat reduction : a post hoc analysis of the AWARD programme", Diabet Med, 35, pp.1434~1439 (2018)
57. Seko Y, "Effect of 12-week dulaglutide therapy in Japanese patients with biopsy-proven non-alcoholic fatty liver disease and type 2 diabetes mellitus", Hepatol Res, 47, pp.1206~1211 (2017)
58. Newsome P, "Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and", or obesity, 2019, pp.50, 193~203
59. Coskun T, "LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus : from discovery to clinical proof of concept", Mol Metab, 18, pp.3~14 (2018)
60. Hartman ML, "Effects of novel dual GIP and GLP-1 receptor agonist tirzepatide on biomarkers of nonalcoholic steatohepatitis in patients with type 2 diabetes", Diabetes Care, 43, pp.1352~1355 (2020)
61. Balaban YH, "Dipeptidyl peptidase IV(DDP IV)in NASH patients", Ann Hepatol, 6, pp.242~250 (2007)
62. Wang X, "Gliptins suppress inflammatory macrophage activation to mitigate inflammation, fibrosis, oxidative stress, and vascular dysfunction in models of nonalcoholic steatohepatitis and liver fibrosis", Antioxid Redox Signal, 28, pp.87~109 (2018)
63. Iwasaki T, "Sitagliptin as a novel treatment agent for non-alcoholic fatty liver disease patients with type 2 diabetes mellitus", Hepatogastroenterology, 58, pp.2103~2105 (2011)
64. Yilmaz Y, "Effects of sitagliptin in diabetic patients with nonalcoholic steatohepatitis", Acta Gastroenterol Belg, 75, pp.240~244 (2012)
65. Kato H, "Effect of sitagliptin on intrahepatic lipid content and body fat in patients with type 2 diabetes", Diabetes Res Clin Pract, 109, pp.199~205 (2015)
66. Fukuhara T, "Efficacy and safety of sitagliptin for the treatment of nonalcoholic fatty liver disease with type 2 diabetes mellitus", Hepatogastroenterology, 61, pp.323~328 (2014)
67. Cui J, "Sitagliptin vs. placebo for non-alcoholic fatty liver disease : a randomized controlled trial", J Hepatol, 65, pp.369~376 (2016)
68. Watanabe T, "Effects of sitagliptin on ectopic fat contents and glucose metabolism in type 2 diabetic patients with fatty liver : a pilot study", J Diabetes Investig, 6, pp.164~172 (2015)
69. Joy TR, "Sitagliptin in patients with non-alcoholic steatohepatitis : a randomized, placebo-controlled trial", World J Gastroenterol, 23, pp.141~150 (2017)
70. Macauley M, "Effect of vildagliptin on hepatic steatosis", J Clin Endocrinol Metab, 100, pp.1578~1585 (2015)
71. Hussain M, "Vildagliptin ameliorates biochemical, metabolic and fatty changes associated with non alcoholic fatty liver disease", Pak J Med Sci, 32, pp.1396~1401 (2016)
72. Hwang HJ, "A dipeptidyl peptidase-IV inhibitor improves hepatic steatosis and insulin resistance by AMPK-dependent and JNK-dependent inhibition of LECT2 expression", Biochem Pharmacol, 98, pp.157~166 (2015)
73. Tobita H, "Alogliptin alleviates hepatic steatosis in a mouse model of nonalcoholic fatty liver disease by promoting CPT1a expression via Thr172 phosphorylation of AMPKα in the liver", Mol Med Rep, 17, pp.6840~6846 (2018)
74. Ideta T, "The dipeptidyl peptidase-4 inhibitor teneligliptin attenuates hepatic lipogenesis via AMPK activation in non-alcoholic fatty liver disease model mice", Int J Mol Sci, 16, pp.29207~29218 (2015)
75. Klein T, "Linagliptin alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis", Med Mol Morphol, 47, pp.137~149 (2014)
76. Mashitani T, "Efficacy of alogliptin in preventing non-alcoholic fatty liver disease progression in patients with type 2 diabetes", Biomed Rep, 4, pp.183~187 (2016)
77. Li JJ, "The efficacy of saxagliptin in T2DM patients with non-alcoholic fatty liver disease: preliminary data", Rev Assoc Med Bras, 65, pp.33~37 (2019)
78. 황유철, "A Lower Baseline Urinary Glucose Excretion Predicts a Better Response to the Sodium Glucose Cotransporter 2 Inhibitor", Diabetes and Metabolism Journal, 43(6), pp.898~905 (2019), 대한당뇨병학회[DOI]
79. 김광실, "The Role of Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Reducing Cardiovascular Events in Patients with Type 2 Diabetes", Endocrinology and Metabolism, 34(2), pp.106~116 (2019), 대한내분비학회[DOI]
80. 최덕현, "Effect of Dapagliflozin on Alanine Aminotransferase Improvement in Type 2 Diabetes Mellitus with Non-alcoholic Fatty Liver Disease", Endocrinology and Metabolism, 33(3), pp.387~394 (2018), 대한내분비학회
81. Kurinami N, "Dapagliflozin significantly reduced liver fat accumulation associated with a decrease in abdominal subcutaneous fat in patients with inadequately controlled type 2 diabetes mellitus", Diabetes Res Clin Pract, 142, pp.254~263 (2018)
82. Tobita H, "Effects of dapagliflozin on body composition and liver tests in patients with nonalcoholic steatohepatitis associated with type 2 diabetes mellitus : a prospective, open-label, uncontrolled study", Curr Ther Res Clin Exp, 87, pp.13~19 (2017)
83. Eriksson JW, "Effects of dapagliflozin and N-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes : a double-blind randomised placebo-controlled study", Diabetologia, 61, pp.1923~1934 (2018)
84. Shimizu M, "Evaluation of the effects of dapagliflozin, a sodium-glucose cotransporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and nonalcoholic fatty liver disease", Diabetes Obes Metab, 21, pp.285~292 (2019)
85. Li B, "Effects of canagliflozin on fatty liver indexes in patients with type 2 diabetes : a meta-analysis of randomized controlled trials", J Pharm Pharm Sci, 21, pp.222~235 (2018)
86. Cusi K, "Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes", Diabetes Obes Metab, 21, pp.812~821 (2019)
87. Inoue M, "Effects of canagliflozin on body composition and hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease", J Diabetes Investig, 10, pp.1004~1011 (2019)
88. Akuta N, "Impact of sodium glucose cotransporter 2 inhibitor on histological features and glucose metabolism of non-alcoholic fatty liver disease complicated by diabetes mellitus", Hepatol Res, 49, pp.531~539 (2019)
89. Sattar N, "Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat : results from randomised trials including the EMPA-REG OUTCOME® trial", Diabetologia, 61, pp.2155~2163 (2018)
90. Lee PCH, "Dapagliflozin and empagliflozin ameliorate hepatic dysfunction among Chinese subjects with diabetes in part through glycemic improvement : a single-center, retrospective, observational study", Diabetes Ther, 9, pp.285~295 (2018)
91. Kuchay MS, "Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease : a randomized controlled trial(E-LIFT Trial)", Diabetes Care, 41, pp.1801~1808 (2018)
92. Miyake T, "Ipragliflozin ameliorates liver damage in non-alcoholic fatty liver disease", Open Med(Wars), 13, pp.402~409 (2018)
93. Ito D, "Comparison of ipragliflozin and pioglitazone effects on nonalcoholic fatty liver disease in patients with type 2 diabetes : a randomized, 24-week, open-label, active-controlled trial", Diabetes Care, 40, pp.1364~1372 (2017)
94. Han E, "Ipragliflozin additively ameliorates non-alcoholic fatty liver disease in patients with type 2 diabetes controlled with metformin and pioglitazone : a 24-week randomized controlled trial", J Clin Med, 9, pp.259~ (2020)
95. Nakano S, "Remogliflozin etabonate improves fatty liver disease in dietinduced obese male mice", J Clin Exp Hepatol, 5, pp.190~198 (2015)
96. Qiang S, "Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus", Diabetol Metab Syndr, 7, pp.104~ (2015)
97. Shibuya T, "Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non-alcoholic fatty liver disease : a prospective randomized controlled pilot study", Diabetes Obes Metab, 20, pp.438~442 (2018)
98. Sumida Y, "Effect of luseogliflozin on hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease : a prospective, single-arm trial(LEAD trial)", Hepatol Res, 49, pp.64~71 (2019)
99. Nozaki Y, "Long-term combination therapy of ezetimibe and acarbose for non-alcoholic fatty liver disease", J Hepatol, 51, pp.548~556 (2009)
100. Komatsu M, "Miglitol attenuates non-alcoholic steatohepatitis in diabetic patients", Hepatol Res, 48, pp.1092~1098 (2018)
101. Ryysy L, "Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients", Diabetes, 49, pp.749~758 (2000)
102. Mazzotti A, "Which treatment for type 2 diabetes associated with non-alcoholic fatty liver disease?", Dig Liver Dis, 49, pp.235~240 (2017)
103. Belete TM, "A recent achievement in the discovery and development of novel targets for the treatment of type-2 diabetes mellitus", J Exp Pharmacol, 12, pp.1~15 (2020)
104. Sookoian S, "Nonalcoholic fatty liver disease and metabolic syndrome : shared genetic basis of pathogenesis", Hepatology, 64, pp.1417~1420 (2016)
105. Sookoian S, "Review article : shared disease mechanisms between non-alcoholic fatty liver disease and metabolic syndrome-translating knowledge from systems biology to the bedside", Aliment Pharmacol Ther, 49, pp.516~527 (2019)
106. Sookoian S, "Genetics of nonalcoholic fatty liver disease : from pathogenesis to therapeutics", Semin Liver Dis, 39, pp.124~140 (2019)

관련 논문AI추천